Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)LeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - Other
Ratios

Amylyx Pharmaceuticals (AMLX) Depreciation & Amortization (IS) (2024 - 2025)

Amylyx Pharmaceuticals (AMLX) has 2 years of Depreciation & Amortization (IS) data on record, last reported at $100000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (IS) fell 50.0% year-over-year to $100000.0; the TTM value through Dec 2025 reached $500000.0, down 44.44%, while the annual FY2025 figure was $500000.0, 44.44% down from the prior year.
  • Depreciation & Amortization (IS) reached $100000.0 in Q4 2025 per AMLX's latest filing, roughly flat from $100000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (IS) topped out at $300000.0 in Q1 2024 and bottomed at $100000.0 in Q2 2025.